Data / Drug companies / Cyclophosphamide
Cyclophosphamide: 22 companies and 81 products in the FDA NDC directory
Cyclophosphamide is listed in the FDA National Drug Code Directory by 22 companies, with 81 products in commercial distribution. 60 of the products (74.1%) are marketed under an abbreviated new drug application (ANDA), the generic route. The most common dosage forms are injection, powder, for solution; capsule; injection, and the newest product started marketing on November 3, 2026.
SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.
- Companies listing it
- 22
- Products
- 81
- Generic (ANDA) products
- 60 (74.1%)
- Application numbers
- 17
- Routes
- Intravenous, Oral
- Brand names
- Frindovyx
- openFDA record search
- api.fda.gov
Companies that list cyclophosphamide
Ranked by number of products. Finished drugs in commercial distribution.
| Company | Products | Main dosage forms | Main marketing category | Newest product started |
|---|---|---|---|---|
| Baxter Healthcare Company | 14 | injection, powder, for solution; tablet | Generic drugs (ANDA) | August 7, 2020 |
| BluePoint Laboratories | 8 | injection, powder, for solution; injection, solution | Generic drugs (ANDA) | March 15, 2026 |
| Avyxa Pharma, LLC | 6 | injection | New drug applications (NDA) | March 19, 2025 |
| Sandoz Inc | 6 | injection, solution, concentrate; injection, powder, for solution | New drug applications (NDA) | April 8, 2024 |
| Amneal Pharmaceuticals LLC | 3 | injection, powder, for solution | Generic drugs (ANDA) | May 31, 2018 |
| Avenacy, LLC | 3 | injection, powder, for solution | Generic drugs (ANDA) | February 1, 2026 |
| Bamboo US Bidco LCC | 3 | injection, powder, for solution | Generic drugs (ANDA) | May 21, 2008 |
| Civica, Inc. | 3 | injection, powder, for solution | Generic drugs (ANDA) | May 21, 2008 |
| Dr. Reddy's Laboratories Inc. | 3 | injection, solution | New drug applications (NDA) | June 20, 2024 |
| Epic Pharma, LLC | 3 | injection, powder, for solution | Generic drugs (ANDA) | June 30, 2024 |
| Eugia US LLC | 3 | injection | New drug applications (NDA) | August 25, 2021 |
| Fresenius Kabi USA, LLC | 3 | injection, powder, for solution | Generic drugs (ANDA) | November 17, 2023 |
| NorthStar Rx LLC | 3 | injection, powder, for solution | Generic drugs (ANDA) | January 8, 2019 |
| Sagent Pharmaceuticals | 3 | injection, powder, lyophilized, for solution | Generic drugs (ANDA) | January 15, 2024 |
| XGen Pharmaceuticals DJB, Inc. | 3 | injection, powder, lyophilized, for solution | Generic drugs (ANDA) | December 19, 2023 |
| Alembic Pharmaceuticals Inc. | 2 | capsule | Generic drugs (ANDA) | November 23, 2022 |
| Alembic Pharmaceuticals Limited | 2 | capsule | Generic drugs (ANDA) | November 23, 2022 |
| Amneal Pharmaceuticals NY LLC | 2 | capsule | Generic drugs (ANDA) | November 3, 2026 |
| Cipla USA Inc. | 2 | capsule | Generic drugs (ANDA) | January 18, 2019 |
| Hikma Pharmaceuticals USA Inc. | 2 | capsule | New drug applications (NDA) | September 16, 2013 |
| Nexus Pharmaceuticals LLC | 2 | injection | Generic drugs (ANDA) | March 30, 2026 |
| Opko Pharmaceuticals, LLC | 2 | capsule | Generic drugs (ANDA) | September 16, 2026 |
Dosage forms
| Dosage form | Products | Share |
|---|---|---|
| Injection, powder, for solution | 42 | 51.9% |
| Capsule | 12 | 14.8% |
| Injection | 11 | 13.6% |
| Injection, powder, lyophilized, for solution | 6 | 7.4% |
| Injection, solution | 5 | 6.2% |
| Injection, solution, concentrate | 3 | 3.7% |
| Tablet | 2 | 2.5% |
Marketing categories
| Marketing category | Products | Share |
|---|---|---|
| Generic drugs (ANDA) | 60 | 74.1% |
| New drug applications (NDA) | 20 | 24.7% |
| Authorized generics (NDA) | 1 | 1.2% |
Updated November 6, 2026. Read from US Food and Drug Administration, National Drug Code Directory (openFDA). CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.